S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Will This Be the Worst U.S. Crisis Ever? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden's Plan to Confiscate Your Cash? (Ad)
Italy's Lake Garda shrinks to near-historic low amid drought
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Germany urged to cap heat in offices this winter to save gas
Will This Be the Worst U.S. Crisis Ever? (Ad)
NASDAQ:MRSN

Mersana Therapeutics - MRSN Stock Forecast, Price & News

$7.57
+0.12 (+1.61%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.50
$7.93
50-Day Range
$2.98
$7.82
52-Week Range
$2.68
$14.80
Volume
1.15 million shs
Average Volume
1.94 million shs
Market Capitalization
$735.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Mersana Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
133.4% Upside
$17.67 Price Target
Short Interest
Healthy
3.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
0.68mentions of Mersana Therapeutics in the last 14 days
Based on 34 Articles This Week
Insider Trading
Acquiring Shares
$2.12 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.69) to ($2.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

157th out of 1,135 stocks

Pharmaceutical Preparations Industry

67th out of 557 stocks

MRSN stock logo

About Mersana Therapeutics (NASDAQ:MRSN) Stock

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright dropped their price objective on shares of Mersana Therapeutics from $24.00 to $19.00 in a report on Monday, May 9th. Robert W. Baird lifted their target price on shares of Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday. SVB Leerink lifted their target price on shares of Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $17.67.

Mersana Therapeutics Price Performance

NASDAQ:MRSN traded up $0.12 on Friday, reaching $7.57. The stock had a trading volume of 1,148,474 shares, compared to its average volume of 1,943,962. The company has a market capitalization of $735.58 million, a P/E ratio of -3.09 and a beta of 1.94. Mersana Therapeutics has a 1-year low of $2.68 and a 1-year high of $14.80. The company has a quick ratio of 4.28, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average price of $4.91 and a 200-day moving average price of $4.30.

Insider Buying and Selling at Mersana Therapeutics

In other news, Director Andrew A. F. Hack purchased 14,760 shares of Mersana Therapeutics stock in a transaction on Thursday, June 2nd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $47,232.00. Following the completion of the transaction, the director now directly owns 8,663,673 shares in the company, valued at $27,723,753.60. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Andrew A. F. Hack purchased 14,760 shares of Mersana Therapeutics stock in a transaction on Thursday, June 2nd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $47,232.00. Following the completion of the transaction, the director now directly owns 8,663,673 shares in the company, valued at $27,723,753.60. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Andrew A. F. Hack bought 100,000 shares of Mersana Therapeutics stock in a transaction dated Friday, May 20th. The shares were bought at an average price of $3.46 per share, for a total transaction of $346,000.00. Following the completion of the transaction, the director now directly owns 8,287,400 shares of the company's stock, valued at approximately $28,674,404. The disclosure for this purchase can be found here. Insiders have bought a total of 647,833 shares of company stock worth $2,123,323 over the last ninety days. Corporate insiders own 4.40% of the company's stock.

Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Stock News Headlines

Mersana Therapeutics (NASDAQ:MRSN) PT Raised to $20.00
Carla Poulson, Chief People Officer of Mersana
Mersana Therapeutics (NASDAQ:MRSN) Shares Gap Up to $5.49
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRSN Company Calendar

Last Earnings
11/09/2021
Today
8/13/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+133.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-170,060,000.00
Net Margins
-3,057.88%
Pretax Margin
-3,057.88%

Debt

Sales & Book Value

Annual Sales
$40,000.00
Price / Sales
18,389.42
Book Value
$1.38 per share

Miscellaneous

Free Float
92,894,000
Market Cap
$735.58 million
Optionable
Not Optionable
Beta
1.94














MRSN Stock - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price forecast for 2022?

5 analysts have issued 12 month target prices for Mersana Therapeutics' shares. Their MRSN share price forecasts range from $14.00 to $20.00. On average, they expect the company's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 133.4% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2022?

Mersana Therapeutics' stock was trading at $6.22 at the start of the year. Since then, MRSN stock has increased by 21.7% and is now trading at $7.57.
View the best growth stocks for 2022 here
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.05. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Mersana Therapeutics had a negative net margin of 3,057.88% and a negative trailing twelve-month return on equity of 140.57%. During the same period in the prior year, the company earned ($0.33) EPS.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (2.05%), Deutsche Bank AG (1.16%), Northern Trust Corp (0.88%), Silverarc Capital Management LLC (0.88%), Renaissance Technologies LLC (0.59%) and BNP Paribas Arbitrage SA (0.56%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger.
View institutional ownership trends
.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $7.57.

How much money does Mersana Therapeutics make?

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $735.58 million and generates $40,000.00 in revenue each year. The company earns $-170,060,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

How many employees does Mersana Therapeutics have?

The company employs 169 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.

This page (NASDAQ:MRSN) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.